{
  "nctId": "NCT02466477",
  "briefTitle": "Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment of Major Depressive Disorder",
  "officialTitle": "A Three-arm, Parallel Group, Multicentre, Double-blind, Randomized Controlled Trial Evaluating the Impact of GeneSight Psychotropic and Enhanced-GeneSight Psychotropic, on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic",
  "protocolDocument": {
    "nctId": "NCT02466477",
    "filename": "Prot_001.pdf",
    "label": "Study Protocol",
    "date": "2017-05-02",
    "uploadDate": "2020-04-28T16:19",
    "size": 2002666,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02466477/document/Prot_001.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE4"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "DOUBLE",
  "enrollmentInfo": {
    "enrollmentCount": 542,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2015-06",
    "completionDate": "2019-09",
    "primaryCompletionDate": "2018-11",
    "firstSubmitDate": "2015-06-03",
    "firstPostDate": "2015-06-09"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* 18 years of age or older;\n* Suffer from a Major Depressive Episode meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria;\n* Have had an inadequate response within the current episode to at least one psychotropic treatment in GEN. Inadequate response is defined as inadequate efficacy after 6 weeks of a psychotropic treatment or discontinuation of a psychotropic treatment due to adverse events (AEs) or intolerability;\n* Have each a score on the 16-item Clinician Quick Inventory of Depressive Symptomatology (QIDS-C16) and 16-item Self-Report Quick Inventory of Depressive Symptomatology (QIDS-SR16) rating scales â‰¥ 11;\n* Be able to understand the requirements of the study and provide written informed consent to participate in this study;\n* Agree to abide by the study protocol and its restrictions and be able to complete all aspects of the study, including all visits and tests.\n\nExclusion Criteria:\n\n* Patients posing a serious suicidal risk and/or in need of immediate hospitalization as judged by the Investigator;\n* Patients with a diagnosis of Bipolar I or II disorder;\n* Patients with a current Axis I diagnosis of:\n\n  * Delirium\n  * Dementia\n  * Amnestic and/or other cognitive disorder\n  * Schizophrenia or other psychotic disorder;\n* Patients having experienced hallucinations, delusions, or any psychotic symptomatology within the current depressive episode or during prior depressive episodes;\n* Patient is currently in an inpatient facility;\n* Patients with a history of hypothyroidism unless taking a stable dose of thyroid medication and asymptomatic or euthyroid for at least 6 months;\n* Patients who meet DSM-IV-TR criteria for any significant current substance use disorder;\n* Patients with:\n\n  * hepatic insufficiency (three times the upper limit of normal (ULN) for aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)); liver transplant recipient; cirrhosis of the liver;\n  * malignancy (except basal cell carcinoma) and/or chemotherapy within 1 year prior to screening; malignancy more than 1 year prior to screening must have been local and without metastasis and/or recurrence, and if treated with chemotherapy, without nervous system complications;\n  * significant unstable medical condition or life threatening disease with - need for therapies that may obscure the results of treatment and/or of the study;\n* Participation in another clinical trial within 30 days of the screening visit;\n* Anticipated inability to attend scheduled study visits;\n* Patients who in the judgment of the Investigator may be unreliable or uncooperative with the evaluation procedure outlined in this protocol;\n* Patients with a history of prior pharmacogenomic testing;\n* Any change in psychotropic medication (including change in dosage) between screening and baseline;\n* Patients currently receiving electroconvulsive therapy (ECT), deep brain stimulation (DBS) or transcranial magnetic stimulation (TMS) treatments, or currently scheduled to receive maintenance treatments of ECT, DBS, or TMS during the course of the study;\n* Patients who self-report to be pregnant or lactating;\n* Patients with a history of gastric bypass surgery.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Change in depressive symptoms as assessed by the 17-item Hamilton Depression (HAM-D17) score",
        "description": "Mean change in the 17-item Hamilton Depression (HAM-D17) score from baseline to Week 8 of the study",
        "timeFrame": "From baseline to Week 8"
      }
    ],
    "secondary": [
      {
        "measure": "Change in depressive symptoms as assessed by the 16-Item Clinician Quick Inventory of Depressive Symptomatology (QIDS-SR16)",
        "timeFrame": "Baseline, Weeks 8 and 12, and Month 12"
      },
      {
        "measure": "Change in depressive symptoms as assessed by the 9-Item Patient Health Questionnaire (PHQ-9)",
        "timeFrame": "Baseline, Weeks 8 and 12, and Month 12"
      },
      {
        "measure": "Change in anxiety symptoms as assessed by theGeneralized Anxiety Disorder 7-Item (GAD-7) Scale",
        "timeFrame": "Baseline, Weeks 8 and 12, and Month 12"
      },
      {
        "measure": "Change in severity of illness as assessed by the Clinical Global Impression of Severity (CGI-S)",
        "timeFrame": "Baseline, Week 12 and Month 12"
      },
      {
        "measure": "Change in global improvement as assessed by the Clinical Global Impression of Improvement (CGI-I)",
        "timeFrame": "Week 12, and Month 12"
      },
      {
        "measure": "Change in global therapeutic benefit and global severity of side effects as assessed by the Clinical Global Impression Efficacy Index",
        "timeFrame": "Week 12 and Month 12"
      },
      {
        "measure": "Changes to initial prescribing based on availability of pharmacogenomic data",
        "timeFrame": "Screening and Baseline"
      },
      {
        "measure": "Response rates to psychotropic medication",
        "description": "A responder is defined as a participant with 50% decrease in HAM-D17 score from baseline.",
        "timeFrame": "Baseline, Weeks 8 and 12, Months 6, 9 and 12"
      },
      {
        "measure": "Remission rates",
        "description": "A remitter is defined as a participant with HAM-D17 score equal or less that 7.",
        "timeFrame": "Baseline, Weeks 8 and 12, Months 6, 9 and 12"
      },
      {
        "measure": "Time to response",
        "timeFrame": "Baseline, Weeks 8 and 12, Months 6, 9 and 12"
      },
      {
        "measure": "Time to remission",
        "timeFrame": "Baseline, Weeks 8 and 12, Months 6, 9 and 12"
      },
      {
        "measure": "Change in psychotropic medication side effects as assessed by the Udvalg for Kliniske Undersogeler (UKU) Side Effect Rating Scale",
        "timeFrame": "Baseline, Weeks 8 and 12, and Month 12"
      },
      {
        "measure": "Change in global measure of side effects (frequency, intensity, and burden domains) as assessed by the Frequency, Intensity, and Burden of Side Effects Ratings (FIBSER)",
        "timeFrame": "Baseline, Weeks 8 and 12, and Month 12"
      },
      {
        "measure": "Weight gain",
        "description": "Subject's weight",
        "timeFrame": "Baseline, Weeks 8 and 12, and Month 12"
      },
      {
        "measure": "Waist-to-hip ratio",
        "description": "Subject's waist and hip measurements",
        "timeFrame": "Baseline, Weeks 8 and 12, and Month 12"
      },
      {
        "measure": "Change in health related quality of life as assessed by the EuroQol (EQ-5D-5L)",
        "timeFrame": "Baseline, Week 12, Months 6, 9 and 12"
      },
      {
        "measure": "Change in health related quality of life as assessed by the Short Form (36) Health Survey (SF-36)",
        "timeFrame": "Baseline, Week 12, Months 6, 9 and 12"
      },
      {
        "measure": "Pharmacogenetics in Psychiatry Follow-up Questionnaire (PIPFQ)",
        "description": "The PIPFQ is a questionnaire developed by CAMH to evaluate each physician's attitude and experience to pharmacogenomic testing. Information is solicited from the physician on three different domains: the processing of the physician's last referral, the contact and outcome of the physician's patient, and the physician's perspective on the future of genetic studies in psychiatric drug treatment.",
        "timeFrame": "Baseline, when prescription changes are made (expected average of every 4 weeks), and Month 12"
      },
      {
        "measure": "Healthcare resource utilization (Composite measure of healthcare costs): physician visits, hospital utilization, emergency department visits, medication use, and laboratory tests",
        "timeFrame": "Baseline, Weeks 8 and 12, Months 6, 9 and 12"
      },
      {
        "measure": "Productivity losses (measured as economic costs)",
        "timeFrame": "Baseline, Weeks 8 and 12, Months 6, 9 and 12"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 20,
      "otherCount": 0,
      "totalCount": 21
    },
    "studyDesign": {
      "phases": [
        "PHASE4"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:29:18.525Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}